Abstract
In Brazil, there has been a significant increase in companies dedicated to research, development, and innovation (R&D&I) to discover new molecules with therapeutic properties. According to "Valor Inovação Brasil 2023," the five largest pharmaceutical companies (Aché, Eurofarma, Roche, Hypera Pharma, and ABBVIE) invested more than R$1.8 billion in R&D&I for new "hits" or "leads" molecules …